About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1NCT00604409

Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer

This trial is testing the safety of combining the oral chemotherapy drug capecitabine with radio-labeled microspheres injected directly into the liver.

Lead sponsor: Fox Chase Cancer Center•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Fox Chase Cancer Center

Collaborators

Sirtex Medical

Patients with adequate liver function and performance status in whom liver-directed therapy and capecitabine would be appropriate are eligible for this clinical trial.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Adequate liver function
•Adequate performance status

Exclusion Criteria

•Significant extrahepatic disease

Related studies

RECRUITINGPhase 1

Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases

NCT05240950 · Colorectal Cancer, Metastatic Liver Cancer

Treat Primary and Metastatic Liver Tumors

NCT05240040 · Intrahepatic Cholangiocarcinoma, Liver Tumor, and more

Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures

NCT05582018 · Hepatocellular Carcinoma, Metastatic Liver Cancer

Not Yet RecruitingEARLY Phase 1

Investigator-initiated Phase I Exploratory Clinical Study of the Safety, Tolerability, and Efficacy of BST02 Injection in the Treatment of Locally Advanced/Metastatic Liver Cancer

NCT06173726 · Locally Advanced/Metastatic Liver Cancer

Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures

NCT04970212 · Carcinoma, Hepatocellular, Metastatic Liver Cancer

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 7, 2015Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment34

Start dateApr 2006

Last updatedSep 7, 2015

Condition

Metastatic Liver Cancer

Locations shown

Fox Chase Cancer Center

Philadelphia, Pennsylvania

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 7, 2015Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions